Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer

Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer

Nivolumab is a humanized IgG4 and programmed death 1 (PD-1) monoclonal antibody that has demonstrated antitumor efficacy in clinical trials of various malignant tumors including non-small-cell lung cancer and head and neck squamous cell carcinoma (SCC). However, patients with multiple primary malign...

Full description

Bibliographic Details
Main Authors: Teppei Yamaguchi, Kazuo Sakurai, Makoto Kuroda, Kazuyoshi Imaizumi, Toyoaki Hida
Format: Article
Language:English
Published: Karger Publishers 2017-09-01
Series:Case Reports in Oncology
Subjects:
Nivolumab
Programmed death 1
Non-small-cell lung cancer
Pharyngeal cancer
Online Access:http://www.karger.com/Article/FullText/479960

Similar Items

Similar Items